Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of products and procedures to transform the treatment of glaucoma. The Company has pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to change the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent Trabecular Micro-Bypass Stent, its first MIGS device. The Company is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression.
Market capitalization (26-Jun-2017)
Closing share price (26-Jun-2017)